Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

BI 655130 Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease